Clinical Trial Update: Safety Study of iCo-007 Intravitreal Injection to Treat Diabetic Macular Edema [Phase 1]

View source ↗

Summary

Phase 1 safety study of intravitreal iCo-007 for diffuse diabetic macular edema has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Macular Edema

Drugs mentioned

• iCo-007

Snippet

Sponsor: iCo Therapeutics Inc. | Conditions: Diffuse Diabetic Macular Edema | Phase 1 | Status: COMPLETED